Company

COMPANY

About Profound

Partners

Profound Medical develops customizable, incision-free therapies which combine real-time Magnetic Resonance (“MR”) imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. We believe TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO® is CE marked and received 510(k) clearance from the U.S. Food and Drug Administration in August 2019.

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

In February, 2016, we entered into a Strategic Agreement with Siemens.

On June 30, 2017, we announced a Definitive Agreement with Philips to Expand Collaboration and Acquire Sonalleve MR-HIFU Business.

On May 11, 2016, we signed a Sales and Marketing Agreement with Philips.

In July 2015, we announced a Joint Development Agreement with Philips.

On December 2020, we entered into a Strategic Agreement with GE

Leadership Team

We have a seasoned leadership team with extensive experience in commercialization of ablation technologies.

Arun Menawat CEO and Chairman of the Board

Dr. Arun Menawat is Chairman and CEO of Profound Medical Inc., a commercial-stage medical technology company that markets real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Profound’s key product is the TULSA-PRO therapeutic system, designed for precise and customizable ablation of diseased prostate tissue.

Before joining Profound, Arun served as the Chairman and CEO of Novadaq Technologies Inc. for 13 years, guiding the company from a startup to one of the fastest growing, NASDAQ listed medical technology companies in North America, with a market cap of mostly over one billion USD during the final three years of his leadership. Earlier, Arun served as President of Cedara Software Corp., a company that developed the industry’s first medical imaging software platform. Today, Cedara’s imaging platform and its big data collection are part of IBM’s Watson Health.

He obtained a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, he was named the EY Ontario Entrepreneur of the Year in the health sciences category.

Tom Tamberrino Chief Commercial Officer

Mr. Tom Tamberrino is a seasoned leader with a distinguished career in sales and marketing leadership, business development, and executive management, with much of his success rooted in the U.S. healthcare industry. He brings a wealth of experience, including a history of entrepreneurial ventures and significant contributions to the medical technology sector. Prior to joining Profound Medical, Mr. Tamberrino served as Vice President of Sales and Marketing at Novadaq Technologies Inc. for several years. Under his leadership, Novadaq established itself as the market leader in near-infrared fluorescence imaging, achieving remarkable growth and driving revenues from an annual run rate of $27 million in 2012 to over $82 million in 2017. This growth culminated in Novadaq’s acquisition by Stryker Corporation for approximately $701 million, after which Mr. Tamberrino continued with Stryker until 2018 to support the integration of Novadaq’s business. Earlier in his career, Mr. Tamberrino held progressive sales management positions at LifeCell Corporation, eventually serving as Area Director. During his time at LifeCell Corporation, he led a 50-person sales team across the Northeastern U.S. and Canada, marketing regenerative tissue matrices. Mr. Tamberrino holds a Bachelor of Science degree in Marketing with a Minor in Psychology from Georgetown University and a Master of Business Administration from Emory University.

Rashed Dewan Chief Financial Officer

Rashed Dewan has over 20 years of finance and accounting experience in public and private companies, with expertise in the medical device sector. Mr. Dewan has extensive experience with systems design and implementation and a strong track record of success in accounting, finance, sales and operations management. Mr. Dewan is a Certified Public Accountant, and has a Bachelor of Science Degree with a concentration in Accounting from the University of Southern California.

Mathieu Burtnyk Chief Operating Officer

Dr. Mathieu Burtnyk has over 15 years experience creating and developing imaging technologies and therapeutic ultrasound solutions, from benchtop to bedside, with a focus on prostate disease. He started his career in academia, obtaining his PhD in Medical Biophysics at the University of Toronto and Sunnybrook Health Sciences Center. He is the inventor of the patented closed-loop temperature feedback control algorithm used by the TULSA-PRO today in clinic. Mathieu joined Profound in 2011, leading the scientific design and execution of pre-clinical through Phase I and TACT Pivotal clinical studies.

Board of Directors

Profound Medical Inc., receives guidance and governance from a Board of Directors that embodies deep experience in the medical device industry and a strong history of success.

Arun Menawat – Chairman

Dr. Menawat joined Profound as Chief Executive Officer in August 2016 and has been a member of the Board for approximately two years prior to joining the Corporation. Previously. Dr. Menawat was the President and Chief Executive Officer of Novadaq Technologies Inc., for 13 years, guiding the company from a start-up to a fast growing, NASDAQ listed medical imaging company in North America, with a market cap of approximately $1 billion at the time of his departure. Previously, Dr. Menawat was President of Cedara, a medical imaging software company and held senior positions at Tenneco Inc. and Hercules Inc.

Dr. Menawat’s educational background includes a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, he was named the EY Ontario Entrepreneur of the Year in the health sciences category.

Arthur L. Rosenthal – Director

Dr. Rosenthal is a director and member of the Compensation Committee for LivaNova PLC, a UK global medical technology company. Prior, Dr. Rosenthal served on the Cyberonics board of directors as a non-executive director and Chair of the Compensation Committee from January 2007 to October 2015. Since June 2010, Dr. Rosenthal has served as a Professor of Practice in the Biomedical Engineering Department at Boston University. Since December 2011, Dr. Rosenthal has also served as CEO of gEyeCue, Ltd., which he co-founded, a development stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening. From June 2011 until July 2012, Arthur served as executive vice-chairman of Cappella Medical Devices Ltd. (now ArraVasc Ltd.), a development-stage company focused on novel device solutions for coronary artery disease. From June 2009 until June 2011, Dr. Rosenthal served as President and CEO of Cappella, Inc. Arthur served as chairman, from January 2002, and CEO, commencing in January 2005, of Labcoat, Ltd. until its acquisition by Boston Scientific Corporation in December 2008. From January 1994 to May 2000, Dr. Rosenthal was a Senior Vice President, Corporate Officer, and Chief Development Officer of Boston Scientific, and from May 2000 until his retirement in January 2005, he was a Senior Vice President, Chief Scientific Officer, and Executive Committee Member of Boston Scientific. From 2000 until 2010, Arthur served as a non-executive director, and from 2006 through 2009, as chairman of the Remuneration Committee, of Renovo, Ltd., a U.K.-based pharmaceutical company that became publicly traded in 2006. In July 2009, Arthur joined the board of Interface Biologics, Inc., a Toronto-based development stage company focused on drug delivery devices, as a non-executive director. In April 2011, Dr. Rosenthal was elected Chairman at Interface Biologics, Inc. From April 2013 to May 2015, Dr. Rosenthal served as a non-executive director and Member of the Compensation Committee of Arch Technologies, Inc. and is currently a member of Arch’s Clinical Advisory Board. In 2015, Dr. Rosenthal was appointed to the Industrial Advisory Committee, CURAM (National University in Galway, Ireland). Dr. Rosenthal is a Fellow of the American Institute of Medical and Biological Engineering since 2003.

Brian Ellacott – Director

Mr. Ellacott is an experienced global medical device executive. Mr. Ellacott joined Belmont Medical Technologies as Chief Executive Officer in December 2017. Belmont is a Boston based private equity owned medical device company with a leading global position in fluid warming and infusion systems. Prior to Belmont, Mr. Ellacott was the President and CEO of Laborie Medical Technologies (“Laborie”). Laborie is a Urology and Gastroenterology medical device company. Mr. Ellacott joined private equity owned Laborie as President and CEO in July 2013 and in four years completed 14 global acquisitions tripling Laborie’s revenue and increasing EBITDA eight fold. Prior to joining Laborie, Mr. Ellacott served as Executive Vice President and General Manager of Invacare’s (NYSE:IVC) $1 billion North and South American homecare and rehabilitation business. Mr. Ellacott has also held executive positions with Baxter International and American Hospital Supply, with assignments in Canada, Australia and the United States. Mr. Ellacott also serves on the board of Belmont and Aspen Surgical. Mr. Ellacott holds a Bachelor of Business Administration Degree from Laurier University, Waterloo, Ontario Canada and is a dual United States and Canadian citizen.

Cynthia Lavoie – Director

Cynthia Lavoie – Director – Dr. Lavoie is currently President and Managing Director of AllosteRx Capital Management (“AllosteRx”). She also serves as President and Chief Investment Officer of CCRM Enterprises. Prior to co-founding AllosteRx, Cynthia was a General Partner with TVM Life Science Management Inc. (“TVM”), a global venture capital group with main offices in Munich and Montreal. She was recruited to TVM from VG (VenGrowth) Partners Inc., where she was a Partner and co-headed its life sciences fund. Along with her role on the board of Profound Medical, Cynthia is currently co-founder and board director of Delta TpX, an immune oncology start-up in Austin, TX and a board director at Fibrocor Therapeutics, a fibrosis company in Toronto. A seasoned healthcare investment professional with 18 years of experience in venture capital, Dr. Lavoie’s expertise includes creating companies de novo and leading investments into businesses developing therapeutics, devices, and diagnostic tools. Cynthia has taken active roles on boards of companies located in Canada and the US from start-up to revenue-generating stages. These include Acer Therapeutics (NASDAQ: ACER), Cytochroma (acquired by OPKO Health), VisualSonics (acquired by SonoSite, now FujiFilm SonoSite), and Trillium Therapeutics (NASDAQ: TRIL). Before joining the investment community, Dr. Lavoie served in a variety of academic and scientific leadership positions for 10 years, working with research institutes and life science companies. Cynthia earned her MBA with first class honors from Rotman School of Management at the University of Toronto and earned her PhD in Molecular Biology with Dean’s honors from McGill University.

Kris Shah – Director

Kris Shah is the president of Baylis Medical Technologies, Inc. (“Baylis”), a leader in the development and commercialization of innovative medical devices in the fields of radiology and neurosurgery. Headquartered in Canada, Baylis also provides contract manufacturing services to some of the world’s leading medical device companies. Kris joined Baylis in 1989 as a co-founder and served as president from 2015 until it was acquired by Boston Scientific in 2022. Baylis is a leading developer, manufacturer, and distributor of specialized medical devices for interventional cardiology. Baylis had previously divested its interventional pain management business to Kimberly Clark Corporation (now Avanos Medical, Inc.) in 2009, and its bone tumor ablation business (OsteoCool) to Medtronic plc in 2016. Kris also co-founded the consulting business OME Group in 1991, which was sold to Ernst and Young in 2011. Kris is an active board member for AdvaMed Accel and Intellijoint Surgical. In the past he has served on the boards of Venture Lab, MEDEC, and the Business Advisory Committee of HTX and Conavi Medical Inc.. His list of accomplishments includes numerous patents, the Ernst and Young Entrepreneur Award for Healthcare in Quebec (2011) and the University of Waterloo Alumni Achievement Award (2014). Kris has a B.Sc. in Electrical Engineering from the University of Waterloo.

Murielle Lortie – Director

Ms. Lortie has an accomplished history of financial leadership success within the global life science industry. She currently serves as CFO at Claridge Investments Inc. Previously, she was Chief Financial Officer of Liminal BioSciences Inc. (“Liminal”), a Nasdaq-listed, clinical-stage biopharmaceutical company. Prior to joining Liminal, Ms. Lortie was Vice President & Chief Financial Officer and Advisor to the CEO, Global Strategy, Mergers & Acquisitions at Pharmascience Inc. Ms. Lortie has held senior positions in finance at Bristol Myers Squibb, including Vice-President of Finance for Bristol Myers Squibb Canada Co. and Global Director of Finance supporting BMS Headquarters.

Ms. Lortie is a Chartered Professional Accountant and member of the Ordre des comptables professionnels agrées du Québec. She holds a Graduate Diploma in Accountancy from Concordia University and a Bachelor of Business Administration Bishop’s University. She has extensive corporate governance experience, previously serving on the Boards of Bellus Health Inc. and Pharmascience Barbados Ltd. & Pharmascience International Ltd. Ms. Lortie is currently a Board member of Finance Executives International (FEI) Canada.

Clinical Advisory Board

Profound Medical’s research and clinical trials are further informed by the considerable collective expertise of well-experienced clinicians, specializing in urology and radiology.

Mark Emberton, OBE FMedSci
Dean, Faculty of Medical Sciences, University College London
Professor of Interventional Oncology, Division of Surgery and Interventional Science, UCL
Honorary Consultant Urologist, UCLH

Michael Fabrizio MD FACS
Professor of Urology
Eastern Virginia Medical School
Urology of Virginia, Past President
Co-Founder, The Atlantic Clinic

Pejman Ghanouni, MD, PhD

Associate Professor of Radiology and, by courtesy, of Neurosurgery, of Obstetrics and Gynecology and of Urology.

Naveen Kella, MD

Board Certified Urologist and Director at the Urology Place

Adam Kibel, MD

Chief of Urology, Brigham and Women’s Hospital
Disease Center Leader, Genitourinary Cancers, Dana-Farber Cancer Institute
Professor of Surgery, Harvard Medical School

Laurence Klotz, MD, FRCSC, CM

Professor of Surgery, University of Toronto
Sunnybrook Chair of Prostate Cancer Research
Chairman, Canadian Urology Research Consortium

Aytekin Oto, MD

Chair, Department of Radiology, University of Chicago
Chief Physician, Head of the Faculty Practice Plan and Dean for Clinical Affairs
Professor of Radiology, University of Chicago
Professor of Surgery, University of Chicago

Neal Shore, MD,FACS

Chief Medical Officer, Surgical Oncology/Urology, Genesis Care, US, Medical Director, Carolina Urologic Research Center.

Preston Sprenkle, MD

Director, Urology Research Fellowship, Urology, Yale School of Medicine, New Haven, CT
Director, Urologic Oncology Clinical Fellowship Program, Urology, Yale School of
Medicine, New Haven, CT
Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology, VA Connecticut Healthcare System, West Haven, CT
Co-Chair, Cancer Liaison Committee, Oncology, VA Connecticut Healthcare
System, West Haven, CT
Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection,
National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA

Edward Steiner, MD

Medical Director and Chief of the WellSpan York Prostate Care Center
Ex-Chairman of Imaging and Radiation Oncology at WellSpan York Hospital PA

Careers

Seeking qualified, committed professionals to join our team.

We are a young, creative and passionate organization committed to making a difference in men’s health with our unique procedure for the ablation of cancerous and non-cancerous prostate tissue.

Our mission is to Profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.

Changing the standard of care is part of our fabric. We are a group of energetic, problem-solvers focused on innovation, and looking to change the world. If you want to make a Profound impact with your career, here is your chance.

We are committed to fostering an inclusive, accessible environment where all employees feel respected and supported. We are dedicated to building a diverse workforce and creating an environment where every employee has the opportunity to reach his/her full potential.

We strive to promote diversity and equal opportunity in the workplace and encourage applications from all qualified individuals.

If selected to participate in the recruitment, selection and/or assessment process, please inform Human Resources of the nature of any accommodation(s) that you may require.

This page lists all current job opportunities which our current employees and the general public can apply for. Those individuals who meet the requirements for a position and are interested in applying should submit their resume and cover letter to hr@profoundmedical.com

Thank you for considering Profound Medical.